{rfName}
Ca

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Pérez-Montero HAuthorStradella AAuthorRecalde SAuthorSoler TAuthorMartinez EAuthorLaplana MAuthorPernas SAuthorFalo CAuthor
Share
Publications
>
Article

Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?

Publicated to:Breast Cancer Research And Treatment. NULL (3): 657-666 - 2021-02-01 NULL(3), DOI: 10.1007/s10549-020-05970-2

Authors: Garcia-Tejedor, A; Fernandez-Gonzalez, S; Ortega, R; Gil-Gil, M; Perez-Montero, H; Fernandez-Montolí, E; Stradella, A; Recalde, S; Soler, T; Petit, A; Bajen, MT; Benitez, A; Guma, A; Campos, M; Pla, MJ; Martinez, E; Laplana, M; Pernas, S; Perez-Sildekova, D; Catala, I; Ponce, J; Falo, C

Affiliations

Hosp Univ Bellvitge, Idibell, Dept Radiol, Multidisciplinary Breast Canc Unit, Barcelona, Spain - Author
Hosp Univ Bellvitge, Idibell, Multidisciplinary Breast Canc Unit, Dept Pathol, Barcelona, Spain - Author
Hosp Univ Bellvitge, Multidisciplinary Breast Canc Unit, Dept Nucl Med, Idibell, Barcelona, Spain - Author
Hosp Univ Bellvitge, Multidisciplinary Breast Canc Unit, Dept Plast & Restorat Surg, Idibell, Barcelona, Spain - Author
Hospital Universitari de Bellvitge - Author
Inst Catala Oncol, Dept Oncol Radiotherapy, Multidisciplinary Breast Canc Unit, Barcelona, Spain - Author
Inst Catala Oncol, Dept Oncol, Multidisciplinary Breast Canc Unit, Barcelona, Spain - Author
Institut català d’Oncologia - Author
Univ Barcelona, Multidisciplinary Breast Canc Unit, Hosp Univ Bellvitge, Dept Gynecol,Idibell,Bellvitge Hosp, Ave Feixa Llarga,Sn, Barcelona 08970, Spain - Author
See more

Abstract

Keywords
Axillary pathologic complete responseDistant disease-free survivalHigh axillary tumour burdenNeoadjuvant chemotherapySentinel lymph node

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Breast Cancer Research And Treatment due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 3.77, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-15, the following number of citations:

  • WoS: 13
  • Scopus: 13
  • Europe PMC: 6
  • OpenCitations: 14
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-15:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 37 (PlumX).
Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (Falo Zamora, Catalina).